AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23151156 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus usual care
Number of subjects: 755
Study 23151156 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 755
Study 23151156 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 755
Study 19701600 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC) performed between 24 and 72 hours after endoscopic retrograde cholangiopancreaticography (ERCP)
Number of subjects: 0
Study 19701600 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC) performed more than 72 hours after endoscopic retrograde cholangiopancreaticography (ERCP)
Number of subjects: 0
Study 17543413 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone once daily for 6 months
Number of subjects: 60
Study 17543413 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 6 months
Number of subjects: 60
Study 15146932 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide 5‐mononitrate (5‐ISMN) tablet
Number of subjects: 18
Study 15146932 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide 5‐mononitrate intravenous infusion
Number of subjects: 18
Study 15146932 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate (ISDN) intravenous infusion
Number of subjects: 18
Study 11219479 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin ER 80 mg QPM
Number of subjects: 695
Study 11219479 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin IR 40 mg QPM
Number of subjects: 695
Study 11219479 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin IR 40 mg BID
Number of subjects: 695
Study 9475657 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 10‐min walks per day (short bouts)
Number of subjects: 47
Study 9475657 — intervention group
Group type: EXPERIMENTAL
Intervention: One 30‐min walk per day (long bouts)
Number of subjects: 47
Study 9475657 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 47
Study 9160550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release (SR) adinazolam
Number of subjects: 202
Study 9160550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 2739019 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilipid A antibody
Number of subjects: 38
Study 2739019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2739019 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 38
Study 474664 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100
Study 474664 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal supplements
Number of subjects: 100
Study 474664 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable supplements
Number of subjects: 100
Study 474664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 100
Study 474664 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro addition of zinc
Number of subjects: 100
Study 31099405 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 60
Study 28723837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5% with epinephrine 5 μg/mL
Number of subjects: 57
Study 26297360 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 220
Study 26297360 — intervention group
Group type: COMPARATOR
Intervention: Sham-RIC (control)
Number of subjects: 220
Study 23782459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 1026
Study 23782459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1026
Study 21324150 — intervention group
Group type: COMPARATOR
Intervention: Standard of care lifestyle intervention
Number of subjects: 0
Study 21324150 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally‐based, matched prescriptive physical activity and diet change program
Number of subjects: 0
Study 19164399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression (group I, n=24)
Number of subjects: 47
Study 19164399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser (group II, n=23)
Number of subjects: 47
Study 17947832 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (1 drop of 0.1% dexamethasone disodium phosphate)
Number of subjects: 55
Study 17947832 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 55
Study 15059069 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) at 1 mg/kg/d
Number of subjects: 105
Study 15059069 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B (c‐AmB) at 0.6 mg/kg/d
Number of subjects: 105
Study 11120550 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellstart‐SLC course training for hospital staff
Number of subjects: 970
Study 11120550 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospitals not exposed to the Wellstart‐SLC course)
Number of subjects: 970
Study 9056026 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual localization task with varying tilt angles (0, 45, 90, 135, 180, 225, 270, 315 degrees)
Number of subjects: 9
Study 8410889 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 79
Study 8410889 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 79
Study 2421751 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol 0.025 mg kg‐1
Number of subjects: 6
Study 2421751 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 1151357 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0
Study 1151357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31211469 — intervention group
Group type: EXPERIMENTAL
Intervention: Typing pattern monitored remotely during a 6-month follow-up while dopaminergic medications were being titrated.
Number of subjects: 61
Study 31211469 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel algorithm based on recursive neural networks for detecting responses to medication.
Number of subjects: 61
Study 31211469 — intervention group
Group type: COMPARATOR
Intervention: Dopaminergic treatment titration.
Number of subjects: 61
Study 30084893 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered interpersonal psychotherapy (tele-IPT)
Number of subjects: 0
Study 26784645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling
Number of subjects: 147
Study 26784645 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 147
Study 24625273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial corticosteroid injection and a physiotherapist-led exercise programme
Number of subjects: 252
Study 24625273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial corticosteroid injection and an advice and exercise leaflet
Number of subjects: 252
Study 24625273 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind subacromial corticosteroid injection and a physiotherapist-led exercise programme
Number of subjects: 252
Study 24625273 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind subacromial corticosteroid injection and an advice and exercise leaflet
Number of subjects: 252
Study 24625273 — intervention group
Group type: COMPARATOR
Intervention: Comparison between injection interventions
Number of subjects: 252
Study 24625273 — intervention group
Group type: COMPARATOR
Intervention: Comparison between exercise interventions
Number of subjects: 252
Study 24625273 — intervention group
Group type: COMPARATOR
Intervention: Long-term outcomes
Number of subjects: 252
Study 23484573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Number of subjects: 42
Study 23484573 — intervention group
Group type: COMPARATOR
Intervention: PlayStation2
Number of subjects: 42
Study 20434602 — intervention group
Group type: EXPERIMENTAL
Intervention: EST+SWC
Number of subjects: 34
Study 20434602 — intervention group
Group type: COMPARATOR
Intervention: SWC
Number of subjects: 34
Study 17923401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil supplementation (FO-S)
Number of subjects: 20
Study 17923401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15741836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen (1.5 mg)
Number of subjects: 7
Study 15741836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11893261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (USG)
Number of subjects: 25
Study 11893261 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 25
Study 11893261 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 25
Study 11893261 — intervention group
Group type: EXPERIMENTAL
Intervention: CT or USG
Number of subjects: 25
Study 10213009 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan (CPT-11) at a dose of 350 mg/m2 every 3 weeks
Number of subjects: 279
Study 10213009 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan (CPT-11)
Number of subjects: 279
Study 7537967 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 11
Study 7537967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight (LMW) heparin
Number of subjects: 11
Study 7537967 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid (danaparoid sodium; Org 10172)
Number of subjects: 11
Study 2170885 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/progestin therapy
Number of subjects: 35
Study 2170885 — intervention group
Group type: COMPARATOR
Intervention: Untreated estrogen-deficient girls
Number of subjects: 35
Study 2170885 — intervention group
Group type: COMPARATOR
Intervention: History of radiation therapy
Number of subjects: 35
Study 696759 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-spatial training condition
Number of subjects: 0
Study 696759 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31365280 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 256
Study 31365280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 256
Study 31365280 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 256
Study 27658337 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw phonation exercises for 3 minutes
Number of subjects: 27
Study 27658337 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw phonation exercises for 5 minutes
Number of subjects: 27
Study 27658337 — intervention group
Group type: COMPARATOR
Intervention: Control group (complete voice rest)
Number of subjects: 27
Study 25785441 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg)
Number of subjects: 76
Study 25785441 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg) + Zinc (30 mg/d) + Selenium (150 μg/d)
Number of subjects: 76
Study 25785441 — intervention group
Group type: COMPARATOR
Intervention: Control (no zinc and selenium supplementation)
Number of subjects: 76
Study 24015990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (200 mg iron sucrose, three daily infusions starting within 24 hours of admission)
Number of subjects: 80
Study 24015990 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care (control group)
Number of subjects: 80
Study 21412833 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 500 mg/day
Number of subjects: 38
Study 21412833 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 1,000 mg/day
Number of subjects: 38
Study 21412833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19477914 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstainers (n = 25)
Number of subjects: 104
Study 19477914 — intervention group
Group type: COMPARATOR
Intervention: Controls (n = 38)
Number of subjects: 104
Study 17184625 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management of oral anticoagulation
Number of subjects: 930
Study 17184625 — intervention group
Group type: COMPARATOR
Intervention: Conventional measurement by the general practitioner
Number of subjects: 930
Study 14749240 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (25 g ground flaxseed muffin)
Number of subjects: 46
Study 14749240 — intervention group
Group type: COMPARATOR
Intervention: Soy (25 g soy flour muffin)
Number of subjects: 46
Study 14749240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 11545629 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin (0.3% ophthalmic solution every 30 minutes for 4 hours before surgery)
Number of subjects: 34
Study 11545629 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (0.3% ophthalmic solution every 30 minutes for 4 hours before surgery)
Number of subjects: 34
Study 11545629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical and oral ofloxacin (one 400-mg tablet administered 24-26, 12-14, and 2 hours before surgery)
Number of subjects: 34
Study 11545629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical and oral ciprofloxacin (four 100-mg tablets administered 24-26, 12-14, and 2 hours before surgery)
Number of subjects: 34
Study 11545629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical and oral therapy with ofloxacin
Number of subjects: 34
Study 11545629 — intervention group
Group type: COMPARATOR
Intervention: Topical therapy alone (ofloxacin)
Number of subjects: 34
Study 9429331 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air convective warming device used for at least 2 hours after the operation
Number of subjects: 0
Study 9429331 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic control group
Number of subjects: 0
Study 8389662 — intervention group
Group type: EXPERIMENTAL
Intervention: ZCE-025
Number of subjects: 32
Study 8389662 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMU-4
Number of subjects: 32
Study 3122381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 20% (250 ml) with moderate hydration (2.5 L)
Number of subjects: 99
Study 3122381 — intervention group
Group type: COMPARATOR
Intervention: Hydration without mannitol
Number of subjects: 99
Study 29876844 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term fasting (36 hours)
Number of subjects: 9
Study 29876844 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (HFD)
Number of subjects: 9
Study 29876844 — intervention group
Group type: COMPARATOR
Intervention: Overnight fast (control)
Number of subjects: 9
Study 28122542 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional follow-up visit (return for follow-up only if signs have not resolved)
Number of subjects: 4300
Study 28122542 — intervention group
Group type: COMPARATOR
Intervention: Universal follow-up visit (return for follow-up regardless of illness resolution)
Number of subjects: 4300
Study 26183420 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative respiratory rehabilitation (PR) for more than 7 days
Number of subjects: 60
Study 26183420 — intervention group
Group type: COMPARATOR
Intervention: No preoperative respiratory rehabilitation (NPR)
Number of subjects: 60
Study 23277304 — intervention group
Group type: EXPERIMENTAL
Intervention: Social learning and cognitive behavioral therapy
Number of subjects: 200
Study 23277304 — intervention group
Group type: COMPARATOR
Intervention: Education and support intervention
Number of subjects: 200
Study 21450262 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining a best possible self (BPS) for 5 minutes per day over two weeks
Number of subjects: 0
Study 21450262 — intervention group
Group type: COMPARATOR
Intervention: Imagining daily activities (DA) for 5 minutes per day over two weeks
Number of subjects: 0
Study 18974717 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg.kg(‐1) body mass
Number of subjects: 8
Study 18974717 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 8
Study 18974717 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 8
Study 18974717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 8
Study 16816222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (mean dose=1515 mg/day)
Number of subjects: 116
Study 16816222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 16816222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 116
Study 12960189 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG brain PET scans in postlingually deaf patients
Number of subjects: 9
Study 12960189 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of glucose metabolism with duration of deafness in postlingually deaf patients
Number of subjects: 9
Study 12960189 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (age- and sex-matched)
Number of subjects: 9
Study 10596684 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin inhalation
Number of subjects: 21
Study 10596684 — intervention group
Group type: COMPARATOR
Intervention: Inhaled L‐ASA (90 mg/mL, 4 mL)
Number of subjects: 21
Study 8537687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal glycoprotein conjugate vaccine (serotypes 6B, 14, 18C, 19F, and 23F linked to CRM197)
Number of subjects: 282
Study 8537687 — intervention group
Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 282
Study 1669628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as an adjuvant to neuroleptanalgesia (NLA)
Number of subjects: 40
Study 1669628 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanalgesia (NLA) alone
Number of subjects: 40
Study 6607696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (used until the night before the operation)
Number of subjects: 145
Study 6607696 — intervention group
Group type: COMPARATOR
Intervention: No cimetidine (not receiving cimetidine in the weeks before operation)
Number of subjects: 145
Study 31725692 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative acetaminophen and carbohydrate drinks
Number of subjects: 100
Study 31725692 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative care (Control)
Number of subjects: 100
Study 30626285 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) for 7 days
Number of subjects: 4011
Study 30626285 — intervention group
Group type: COMPARATOR
Intervention: No GTN (control)
Number of subjects: 4011
Study 28251606 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative continuous positive airway pressure (CPAP)
Number of subjects: 135
Study 28251606 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 135
Study 28251606 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 135
Study 24910161 — intervention group
Group type: EXPERIMENTAL
Intervention: Burping
Number of subjects: 71
Study 24910161 — intervention group
Group type: COMPARATOR
Intervention: No-burping (Control)
Number of subjects: 71
Study 24369008 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-led group intervention
Number of subjects: 241
Study 24369008 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed individual intervention
Number of subjects: 241
Study 24369008 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241
Study 22167079 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with Improvac (2 ml s. c.); administered at 12 weeks and 18 weeks
Number of subjects: 396
Study 22167079 — intervention group
Group type: COMPARATOR
Intervention: Surgical castration
Number of subjects: 396
Study 22167079 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with Improvac
Number of subjects: 396
Study 20020791 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic + intravenous ketorolac tromethamine
Number of subjects: 27
Study 20020791 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac tromethamine alone
Number of subjects: 27
Study 17093067 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG+SPIRO
Number of subjects: 260
Study 17093067 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG+HCTZ
Number of subjects: 260
Study 17093067 — intervention group
Group type: COMPARATOR
Intervention: RSG-C
Number of subjects: 260
Study 17093067 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG+FRUS
Number of subjects: 260
Study 15068574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, nurse-administered smoking cessation intervention with telephone counseling
Number of subjects: 56
Study 12033074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup-feeding (CF)
Number of subjects: 78
Study 12033074 — intervention group
Group type: COMPARATOR
Intervention: Bottle-feeding (BF)
Number of subjects: 78
Study 9701406 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg x m(‐3) NO2 for 30 min
Number of subjects: 16
Study 9701406 — intervention group
Group type: COMPARATOR
Intervention: Purified air
Number of subjects: 16
Study 7768259 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan (16 mg)
Number of subjects: 0
Study 7768259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (up to 400 mg)
Number of subjects: 0
Study 7768259 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 0
Study 7768259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan
Number of subjects: 0
Study 2138237 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) 0.02 micrograms/kg.min i.v.
Number of subjects: 6
Study 2138237 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 6
Study 2138237 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone
Number of subjects: 6
Study 2138237 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP with Amiloride
Number of subjects: 6
Study 2138237 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP
Number of subjects: 6
Study 373358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine therapy
Number of subjects: 38